327 related articles for article (PubMed ID: 11726570)
1. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix).
Garcia-Velasco JA; Isaza V; Vidal C; Landazábal A; Remohí J; Simón C; Pellicer A
Hum Reprod; 2001 Dec; 16(12):2533-9. PubMed ID: 11726570
[TBL] [Abstract][Full Text] [Related]
2. Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist.
Giampietro F; Sancilio S; Tiboni GM; Rana RA; Di Pietro R
Fertil Steril; 2006 Feb; 85(2):412-9. PubMed ID: 16595220
[TBL] [Abstract][Full Text] [Related]
3. Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization.
Fornaro F; Cobellis L; Mele D; Tassou A; Badolati B; Sorrentino S; De Lucia D; Colacurci N
Fertil Steril; 2007 Jan; 87(1):39-47. PubMed ID: 17084393
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
5. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction.
Yding Andersen C; Westergaard LG; Figenschau Y; Bertheussen K; Forsdahl F
Hum Reprod; 1993 Jun; 8(6):840-3. PubMed ID: 8345072
[TBL] [Abstract][Full Text] [Related]
6. Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro-results of a prospective, randomized in-vitro fertilization study.
Dor J; Bider D; Shulman A; Levron JL; Shine S; Mashiach S; Rabinovici J
Hum Reprod; 2000 Jun; 15(6):1225-30. PubMed ID: 10831545
[TBL] [Abstract][Full Text] [Related]
7. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone agonist and antagonists, on follicular fluid stem cell factor and serum urocortin 1 levels on the day of oocyte retrieval.
Celik O; Celik E; Yilmaz E; Celik N; Turkcuoglu I; Ulas M; Kumbak B; Aktan E; Ozerol I
Arch Gynecol Obstet; 2013 Dec; 288(6):1417-22. PubMed ID: 23801011
[TBL] [Abstract][Full Text] [Related]
8. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
9. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
10. Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles.
Ferrari B; Pezzuto A; Barusi L; Coppola F
Eur J Obstet Gynecol Reprod Biol; 2006 Jan; 124(1):70-6. PubMed ID: 16183188
[TBL] [Abstract][Full Text] [Related]
11. Effect of progesterone pre-treatment on steroid secretion rates and follicular fluid insulin-like growth factor-1 concentrations in seasonally anoestrous ewes treated with gonadotrophin releasing hormone.
Khalid M; Basiouni GF; Haresign W
Anim Reprod Sci; 1997 Mar; 46(1-2):69-78. PubMed ID: 9231248
[TBL] [Abstract][Full Text] [Related]
12. IGF-I and epidermal growth factor levels in follicular fluid of women undergoing controlled ovarian hyperstimulation using the multidose GnRH-antagonist protocol or the long GnRH-agonist protocol.
Asimakopoulos B; Schöpper B; Dawson A; Caglar GS; Vakalopoulos I; Al-Hasani S; Diedrich K; Nikolettos N
J Endocrinol Invest; 2006 May; 29(5):RC5-8. PubMed ID: 16794358
[TBL] [Abstract][Full Text] [Related]
13. Human chorionic gonadotrophin and steroid concentrations in follicular fluid: the relationship to oocyte maturity and fertilization rates in stimulated and natural in-vitro fertilization cycles.
Enien WM; el Sahwy S; Harris CP; Seif MW; Elstein M
Hum Reprod; 1995 Nov; 10(11):2840-4. PubMed ID: 8747029
[TBL] [Abstract][Full Text] [Related]
14. The effect of a potent gonadotrophin-releasing hormone antagonist on ovarian secretion of oestradiol, inhibin and androstenedione and the concentration of LH and FSH during the follicular phase of the sheep oestrous cycle.
Campbell BK; McNeilly AS; Picton HM; Baird DT
J Endocrinol; 1990 Sep; 126(3):377-84. PubMed ID: 2120381
[TBL] [Abstract][Full Text] [Related]
15. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
16. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction.
Tarlatzis BC; Pazaitou K; Bili H; Bontis J; Papadimas J; Lagos S; Spanos E; Mantalenakis S
Hum Reprod; 1993 Oct; 8(10):1612-6. PubMed ID: 8300815
[TBL] [Abstract][Full Text] [Related]
18. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
[TBL] [Abstract][Full Text] [Related]
19. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme.
Kamel MA; Zabel G; Bernart W; Neulen J; Breckwoldt M
Hum Reprod; 1994 Oct; 9(10):1803-6. PubMed ID: 7844206
[TBL] [Abstract][Full Text] [Related]
20. Comparison of follicular fluid amphiregulin and EGF concentrations in patients undergoing IVF with different stimulation protocols.
Liu N; Ma Y; Li R; Jin H; Li M; Huang X; Feng HL; Qiao J
Endocrine; 2012 Dec; 42(3):708-16. PubMed ID: 22678853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
